Table 1.
Baseline Data
| Variable | Total | Doxycycline | Amoxicillin | Placebo | P Value |
|---|---|---|---|---|---|
| Patients (male/female), No. | 119 (34/85) | 46 (10/36) | 35 (9/26) | 38 (15/23) | .198a |
| CFA positive | 46 (17/29) | 19 (5/14) | 13 (6/7) | 14 (6/8) | .471a |
| CFA negative | 73 (17/56) | 27 (5/22) | 22 (3/19) | 24 (9/15) | .153a |
| LE stage 1 | 2 (0/2) | 1 (0/1) | 1 (0/1) | 0 | |
| LE stage 2 | 53 (16/37) | 20 (5/15) | 18 (4/14) | 15 (7/8) | |
| LE stage 3 | 57 (15/42) | 23 (4/19) | 15 (5/10) | 19 (6/13) | |
| LE stage 4 | 1 (0/1) | 1 (0/1) | 0 | 0 | |
| LE stage 5 | 6 (3/3) | 1 (1/0) | 1 (0/1) | 4 (2/2) | |
| Age, mean ± SD, years | 47.7 ± 10.8 | 46.1 ± 11.6 | 51.3 ± 9.1 | 46.3 ± 10.9 | .045b |
| CFA positive | 49.7 ± 12.1 | 45.5 ± 13.9 | 56.0 ± 5.6 | 49.4 ± 12.1 | .045b |
| CFA negative | 46.5 ± 9.8 | 46.5 ± 9.9 | 48.6 ± 9.7 | 44.5 ± 9.9 | .304b |
| Duration of LE, mean ± SD, years | 13.8 ± 12.3 | 13.7 ± 11.8 | 14.6 ± 14.9 | 13.3 ± 10.5 | .893b |
| CFA positive | 11.5 ± 12.7 | 9.3 ± 10.2 | 12.2 ± 16.5 | 13.7 ± 12.3 | .475b |
| CFA negative | 15.3 ± 11.9 | 16.9 ± 11.9 | 16.0 ± 14.1 | 13.0 ± 9.5 | .554b |
| MDA/total, No. (%) | |||||
| 2006 | 87/117 (74) | 31/46 (67.4) | 28/34 (82.4) | 28/37 (75.7) | .329a |
| 2007 | 85/115 (74) | 30/44 (68.2) | 27/34 (79.4) | 28/37 (75.7) | .535a |
| 2008 | 75/109 (69) | 25/41 (61.0) | 24/31 (77.4) | 26/37 (70.3) | .347a |
Abbreviations: CFA, circulating filarial antigen; LE, lymphedema; MDA, mass drug administration (ivermectin plus albendazole); SD, standard deviation.
a Fisher's exact test.
b Kruskal-Wallis test.